


# MONARCH 3 STUDY DESIGN<sup>3</sup>


MONARCH 3: a phase III, multinational, randomised, double-blind, placebo-controlled trial



\*Each cycle was 28 days. BID = twice daily MBC = metastatic breast cancer PO = orally

## DESIGNED FOR HER EVERY DAY

- Verzenio is a CDK4 & 6 inhibitor with continuous dosing<sup>1</sup>
- All subgroups benefited from Verzenio + AI<sup>2</sup>



Reference:  
 1. Verzenio PI Singapore October 2021. Last accessed 17 Oct 2021.  
 2. Di Leo A, O'Shaughnessy J, Sledge GW, et al. Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy. npj Breast Cancer. 2018;4:41.  
 3. Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35:3638-3646.

Market Expansion Services by [www.dksh.com](http://www.dksh.com)

**DKSH Singapore Pte Ltd**  
 47 Jalan Buroh, #09-01, Singapore 619491  
 Phone +65 6471 1466



Before prescribing Verzenio (abemaciclib), please consult the full local prescribing information by scanning the following QR code.

**SAFETY REPORTING FOR POTENTIAL UNDESIRABLE EFFECTS:**  
 Please report adverse events to the DKSH Singapore Pte Ltd at HEC-RA.Sin@dksh.com